These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 25122671)

  • 21. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
    Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
    Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
    Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
    Bauer S; Jones RL; Blay JY; Gelderblom H; George S; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Su Y; Meade J; Wang T; Sherman ML; Ruiz-Soto R; Heinrich MC
    J Clin Oncol; 2022 Dec; 40(34):3918-3928. PubMed ID: 35947817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
    Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
    Paz-Ares L; García del Muro X; Grande E; González P; Brosa M; Díaz S
    Clin Transl Oncol; 2008 Dec; 10(12):831-9. PubMed ID: 19068454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
    Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
    Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
    Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
    BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.
    Chen YY; Yeh CN; Cheng CT; Chen TW; Rau KM; Jan YY; Chen MF
    World J Gastroenterol; 2011 Apr; 17(16):2113-9. PubMed ID: 21547131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
    Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
    Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
    Liu X; Jiang WZ; Guan GX; Chen ZF; Chi P; Lu HS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):221-5. PubMed ID: 23536339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
    Kang YK; Yoo C; Ryoo BY; Lee JJ; Tan E; Park I; Park JH; Choi YJ; Jo J; Ryu JS; Ryu MH
    Br J Cancer; 2013 Oct; 109(9):2309-15. PubMed ID: 24084771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
    George S; Reichardt P; Lechner T; Li S; Cohen DP; Demetri GD
    Ann Oncol; 2012 Dec; 23(12):3180-3187. PubMed ID: 22858558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
    Kim EJ; Zalupski MM
    J Surg Oncol; 2011 Dec; 104(8):901-6. PubMed ID: 22069175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C-kit, GIST, and imatinib.
    Siehl J; Thiel E
    Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
    J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
    Kim KP; Ryu MH; Yoo C; Ryoo BY; Choi DR; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):285-91. PubMed ID: 20957481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.
    Cauchi C; Somaiah N; Engstrom PF; Litwin S; Lopez M; Lee J; Davey M; Bove B; von Mehren M
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):977-82. PubMed ID: 22119758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Focus on GIST management].
    Tardieu M; Dômont J; Cioffi A; Bonvalot S; Le Cesne A
    Bull Cancer; 2010 Jun; 97(6):723-31. PubMed ID: 20483709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.